SOURCE: Dynavax Technologies

Dynavax Technologies

January 10, 2014 17:00 ET

Dynavax to Present at the 32nd Annual J.P. Morgan Healthcare Conference

BERKELEY, CA--(Marketwired - Jan 10, 2014) - Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that it will present at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 16, 2014 at 9:30 a.m. Pacific Time (12:30 p.m. Eastern Time).

Eddie Gray, Chief Executive Officer of Dynavax, will provide a company overview. To access the slide presentation, live webcast, and subsequent archived recording, please visit Dynavax's website at http://investors.dynavax.com/newsevents.cfm.

About Dynavax

Dynavax, a clinical-stage biopharmaceutical company, discovers and develops novel vaccines and therapeutics in the areas of infectious and inflammatory diseases and oncology. Dynavax's lead product candidate is HEPLISAV, a Phase 3 investigational adult hepatitis B vaccine. For more information visit www.dynavax.com.

Contact Information

  • Contact:
    Michael Ostrach
    Vice President and Chief Business Officer
    510-665-7257
    Email Contact